Overview

A Bioequivalence Study of Bimekizumab Given as 1x2ml or 2x1ml Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the pharmacokinetics (PK), safety and tolerability of a single subcutaneous (sc) dose of bimekizumab (BKZ) when administered using bimekizumab-autoinjector (AI)-2mL presentation versus bimekizumab-AI-2x1mL presentation in healthy study participants.
Phase:
Phase 1
Details
Lead Sponsor:
UCB Biopharma SRL